Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 177 results
July 2024
-
Key ReleaseNovartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidanceAd hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+…
-
Key ReleaseNovartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehobenAd-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im zweiten Quartal um +11% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +19% (kWk, +17% USD) Das Umsatzwachstum…
January 2024
-
Key ReleaseNovartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readoutsAd hoc announcement pursuant to Art. 53 LRFull year (continuing operations2)Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD)Sales growth was mainly driven by…
-
Key ReleaseStarkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-ErgebnissenAd-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr (fortzuführende Geschäftsbereiche2)Der Nettoumsatz wuchs um +10% (kWk, +8% USD), und das operative Kernergebnis verbesserte sich um +18% (…
November 2023
-
Key ReleaseNovartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D DayAd hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent…
-
Media ReleaseNovartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria…
October 2023
-
Media ReleaseFDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decadeFDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21 As the only IL-17A inhibitor…
-
Key ReleaseNovartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidanceAd hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing…
-
Key ReleaseNovartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines companyAd hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-offShares of Sandoz will be listed and…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 15
- › Next page